Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non Operating Income: 2014-2024

Historic Non Operating Income for Ultragenyx Pharmaceutical (RARE) over the last 11 years, with Dec 2024 value amounting to -$4.0 million.

  • Ultragenyx Pharmaceutical's Non Operating Income fell 133.90% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 199.17%. This contributed to the annual value of -$4.0 million for FY2024, which is 1075.96% down from last year.
  • As of FY2024, Ultragenyx Pharmaceutical's Non Operating Income stood at -$4.0 million, which was down 1,075.96% from -$337,000 recorded in FY2023.
  • Ultragenyx Pharmaceutical's Non Operating Income's 5-year high stood at $607,000 during FY2020, with a 5-year trough of -$4.0 million in FY2024.
  • Its 3-year average for Non Operating Income is -$2.0 million, with a median of -$1.6 million in 2022.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Non Operating Income spiked by 177.13% in 2020, and later slumped by 1,075.96% in 2024.
  • Ultragenyx Pharmaceutical's Non Operating Income (Yearly) stood at $607,000 in 2020, then plummeted by 377.92% to -$1.7 million in 2021, then increased by 7.17% to -$1.6 million in 2022, then skyrocketed by 78.48% to -$337,000 in 2023, then plummeted by 1,075.96% to -$4.0 million in 2024.